Gates Foundation Offers $4 Million to Fix Syringe Shortage for Covid Shots
(Bloomberg) -- The Bill & Melinda Gates Foundation is stepping up efforts to address a looming deficit of syringes for Covid shots, providing about $4 million to help Kenyan manufacturer Revital Healthcare more than triple production.
Shortages of syringes and other supplies are threatening to complicate the rollout of Covid vaccines just as shipments to lower-income nations begin to pick up after months of delays. Lack of funds, transportation and training are also among the delivery challenges that could slow distribution.
Narrowing a glaring gap in access to Covid shots remains the top concern, especially in Africa, where just 6% of the population is fully vaccinated. Covax, the World Health Organization-backed program to distribute Covid vaccines to every corner of the world, has fallen short of its targets this year. Getting those vaccines into arms is now the next challenge.
“It's hard to plan for vaccine plenty when you are in the middle of vaccine poverty, but that is about to change, and it's important that we also change,” Orin Levine, director of the Gates Foundation's global delivery programs, said in an interview.
Unprecedented Demand
Countries such as Kenya, Rwanda and South Africa are already facing delays in obtaining syringes. Four others, including Djibouti and the Democratic Republic of Congo, have struggled to give people the doses they have, using less than half of what they've received, the WHO wrote in an email Wednesday.
When it comes to syringes, export restrictions and rising freight costs are hampering efforts to keep up with unprecedented demand, said Surabhi Rajaram, a Gates program officer. India and China account for most manufacturing of auto-disable vaccine syringes, which lock automatically to prevent reuse.
Although Unicef has tripled orders, further steps are needed. The child health program has estimated a potential shortfall of as many as 2.2 billion syringes for Covid vaccines and routine immunizations in 2022.
“There are definitely shortages that are likely to manifest over the course of next year,” Rajaram said.
Another challenge is that “the entire world is set up to give vaccinations” using 0.5 milliliter syringes, Levine said. The Pfizer Inc.-BioNTech SE shot, meanwhile, requires 0.3 milliliter syringes that are in short supply. Gates and others have sought to shift to manufacturing of that syringe without disrupting supplies of the other, he said.
The funds will allow Revital to boost syringe production to a level that's enough to cover more than half of the routine immunization needs in Africa, according to a statement. The insufficient supply globally is a dilemma that's been overlooked, according to Roneek Vora, director of sales, marketing and development at Revital.
“It's a major concern for various countries in Africa,” he said. “If they can't get the syringes in time, these vaccines basically are going to be of no use.”
©2021 Bloomberg L.P.
(Corrects web headline that contained wrong figure on the Gates donation)
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.